These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29407978)

  • 1. New hydrazides derivatives of isoniazid against Mycobacterium tuberculosis: Higher potency and lower hepatocytotoxicity.
    Castelo-Branco FS; de Lima EC; Domingos JLO; Pinto AC; Lourenço MCS; Gomes KM; Costa-Lima MM; Araujo-Lima CF; Aiub CAF; Felzenszwalb I; Costa TEMM; Penido C; Henriques MG; Boechat N
    Eur J Med Chem; 2018 Feb; 146():529-540. PubMed ID: 29407978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoniazid derivatives and their anti-tubercular activity.
    Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
    Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four hydrazide compounds that inhibit the growth of mycobacterium tuberculosis.
    Bartzatt R; Cirillo SL; Cirillo JD
    Physiol Chem Phys Med NMR; 2008; 40():55-65. PubMed ID: 20070040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of new cinnamic derivatives as antituberculosis agents.
    De P; Koumba Yoya G; Constant P; Bedos-Belval F; Duran H; Saffon N; Daffé M; Baltas M
    J Med Chem; 2011 Mar; 54(5):1449-61. PubMed ID: 21309577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoniazid-phytochemical conjugation: A new approach for potent and less toxic anti-TB drug development.
    Swain SS; Paidesetty SK; Padhy RN; Hussain T
    Chem Biol Drug Des; 2020 Aug; 96(2):714-730. PubMed ID: 32237023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
    Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
    Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower cytotoxicity, high stability, and long-term antibacterial activity of a poly(methacrylic acid)/isoniazid/rifampin nanogel against multidrug-resistant intestinal Mycobacterium tuberculosis.
    Chen T; Li Q; Guo L; Yu L; Li Z; Guo H; Li H; Zhao M; Chen L; Chen X; Zhong Q; Zhou L; Wu T
    Mater Sci Eng C Mater Biol Appl; 2016 Jan; 58():659-65. PubMed ID: 26478357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Introduction of Hydrazone, Hydrazide, or Azepane Moieties to the Triterpenoid Core Enhances an Activity Against
    Kazakova OB; Medvedeva NI; Smirnova IE; Lopatina TV; Veselovsky AV
    Med Chem; 2021; 17(2):134-145. PubMed ID: 31939731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy.
    Laborde J; Deraeve C; de Mesquita Vieira FG; Sournia-Saquet A; Rechignat L; Villela AD; Abbadi BL; Macchi FS; Pissinate K; Bizarro CV; Machado P; Basso LA; Pratviel G; de França Lopes LG; Sousa EHS; Bernardes-Génisson V
    J Inorg Biochem; 2018 Feb; 179():71-81. PubMed ID: 29175704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing new antitubercular isoniazid derivatives with improved reactivity and membrane trafficking abilities.
    de Faria CF; Moreira T; Lopes P; Costa H; Krewall JR; Barton CM; Santos S; Goodwin D; Machado D; Viveiros M; Machuqueiro M; Martins F
    Biomed Pharmacother; 2021 Dec; 144():112362. PubMed ID: 34710838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiosemicarbazones, semicarbazones, dithiocarbazates and hydrazide/hydrazones: anti-Mycobacterium tuberculosis activity and cytotoxicity.
    Pavan FR; da S Maia PI; Leite SR; Deflon VM; Batista AA; Sato DN; Franzblau SG; Leite CQ
    Eur J Med Chem; 2010 May; 45(5):1898-905. PubMed ID: 20163897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
    Rodrigues MO; Cantos JB; D'Oca CR; Soares KL; Coelho TS; Piovesan LA; Russowsky D; da Silva PA; D'Oca MG
    Bioorg Med Chem; 2013 Nov; 21(22):6910-4. PubMed ID: 24103427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of highly potent novel anti-tubercular isoniazid analogues with preliminary pharmacokinetic evaluation.
    Ramani AV; Monika A; Indira VL; Karyavardhi G; Venkatesh J; Jeankumar VU; Manjashetty TH; Yogeeswari P; Sriram D
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2764-7. PubMed ID: 22440626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of novel 1,2,3-triazole derivatives of isoniazid and their in vitro and in vivo antimycobacterial activity evaluation.
    Kumar D; Beena ; Khare G; Kidwai S; Tyagi AK; Singh R; Rawat DS
    Eur J Med Chem; 2014 Jun; 81():301-13. PubMed ID: 24852277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitubercular activity of Ru (II) isoniazid complexes.
    Aguiar Id; Tavares A; Roveda AC; da Silva AC; Marino LB; Lopes ÉO; Pavan FR; Lopes LG; Franco DW
    Eur J Pharm Sci; 2015 Apr; 70():45-54. PubMed ID: 25638418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microwave assisted one-pot synthesis of highly potent novel isoniazid analogues.
    Manjashetty TH; Yogeeswari P; Sriram D
    Bioorg Med Chem Lett; 2011 Apr; 21(7):2125-8. PubMed ID: 21320779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversity oriented design of various hydrazides and their in vitro evaluation against Mycobacterium tuberculosis H37Rv strains.
    Manvar A; Bavishi A; Radadiya A; Patel J; Vora V; Dodia N; Rawal K; Shah A
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4728-31. PubMed ID: 21752642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
    Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
    Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Note on Derivatives of Isoniazid, Rifampicin, and Pyrazinamide Showing Activity Against Resistant Mycobacterium tuberculosis.
    Nusrath Unissa A; Hanna LE; Swaminathan S
    Chem Biol Drug Des; 2016 Apr; 87(4):537-50. PubMed ID: 26613382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.